Business
Epistem to Announce Data on Its Stem Cell Cance...
Epistem to Announce Data on Its Stem Cell Cance....
About this update from Genedrive Plc
[{"type":"text","content":"\n \n\n\n\nMANCHESTER, UK--(Marketwire - April 04, 2008) - Epistem Plc (LSE:\nEHP), the UK epithelial stem cell company, announced today that data\non its cancer stem cell assays will be presented at the international\nmeeting of the American Association for Cancer Research (AACR) at the\nSan Diego Convention Center, California, USA from 13th to 16th April\n2008.\n\nIt has been suggested that tumours are derived from a small\nsubpopulation of \"cancer stem cells.\" If these stem cells are not\naffected by a cancer therapy the treatment is only likely to be\npalliative and the tumour will re-grow. Epistem are currently\ndeveloping and validating cancer stem cell assays to test the effect\nof novel cancer agents on this cell type to help identify more\neffective treatments.\n\nThe poster presentation will demonstrate that a key regulator of\nepithelial stem cells, discovered by Epistem's Novel Therapies\nDivision, inhibits the growth of cancer stem cells. Epistem have\nassayed the protein in an in vitro cancer stem cell assay and have\nshown it to reduce the formation of breast cancer spheres\n(mammospheres) four-fold. Epistem's Contract Research Division also\nprovides the cancer stem cell assay on a contract basis for other\npharmaceutical and biotechnology companies.\n\nAn abstract can be viewed on the AACR website at www.aacr.org or\nunder 'latest news' on the Epistem website at www.epistem.co.uk\n\n\n\nThis information is provided by RNS\nThe company news service from the London Stock Exchange\n\n\nFor further information, please contact:\n\nMatthew Walls\nChief Executive Officer\nEpistem Plc\n+44 (0)161 606 7258\n+44 (0)7887 501998\n\nMike Wort / Anna Dunphy\nFinancial PR/IR\nDe Facto Communications\n+44 (0) 207 861 3838\n\n\n\n\n\n\n \n ","length":1773,"tagName":"div"}]